Health
Japan has approved Eisai and Biogen’s Leqembi treatment for Alzheimer’s disease
Japanese company Eisai has announced that its Alzheimer’s disease treatment developed with Biogen, Leqembi, has been approved by the country’s Ministry of Health, making it
Novartis confirms the spin-off of Sandoz on 4 October 2023
Novartis on Monday confirmed its plans for a 100% spin-off of its Sandoz business on 4 October after shareholders gave their approval earlier this month.
Novo Nordisk and Valo to research cardiometabolic treatments
Danish drugmaker Novo Nordisk announced it will collaborate with US technology company Valo Health to discover and develop new treatments for cardiometabolic diseases using human
U.S. FDA finds violations at Novo’s main U.S. plant in May 2022
Back in May last year, U.S. drug regulators published a report detailing quality control violations at Novo Nordisk’s main North American plant, according to a
The US government has allocated $45 million for long-term COVID clinics
The U.S. government is awarding $45 million in grants to help clinics treating protracted COVID develop new models of care and expand access, the Department
The U.S. government has resumed delivery of free COVID tests
The U.S. Department of Health and Human Services said Wednesday it will deliver free COVID-19 tests to households nationwide. Starting 25 September, households will again
In Germany, the incidence of COVID-19 has increased
Germany reported a record high seven days of coronavirus cases, just a few days before a planned easing of restrictions. 198,888 new cases of infection
Vaccination with Novavax in the EU has started slowly
Demand for Novavax’s COVID-19 vaccine was underwhelming in the core countries of the European Union during the initial rollout. More than 85% of adults in
Japan: suicides among women increase for the second year
The number of women who commit suicide in Japan rose for the second year in a row in 2021, although the total number of people
US does not approve AstraZeneca for chronic nasal disease
AstraZeneca said the US regulator has refused to approve the asthma drug Fasenra for the treatment of chronic rhinosinusitis with nasal polyps, a condition characterized